Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer

Megan Multhaup, Andrea D. Karlen, Debra L. Swanson, Andrew Wilber, Nikunj V Somia, Morton J. Cowan, R S Mc Ivor

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Artemis is a hairpin-opening endonuclease involved in nonhomologous end-joining and V(D)J recombination. Deficiency of Artemis results in radiation-sensitive severe combined immunodeficiency (SCID) characterized by complete absence of T and B cells due to an arrest at the receptor recombination stage. We have generated several lentiviral vectors for transduction of the Artemis sequence, intending to complement the deficient phenotype. We found that transduction by a lentiviral vector in which Artemis is regulated by a strong EF-1α promoter resulted in a dose-dependent loss of cell viability due to perturbed cell cycle distribution, increased DNA damage, and increased apoptotic cell frequency. This toxic response was not observed in cultures exposed to identical amounts of control vector. Loss of cell viability was also observed in cells transfected with an Artemis expression construct, indicating that toxicity is independent of lentiviral transduction. Reduced toxicity was observed when cells were transduced with a moderate-strength phosphoglycerate kinase promoter to regulate Artemis expression. These results present a novel challenge in the establishment of conditions that support Artemis expression at levels that are nontoxic yet sufficient to correct the T-B - phenotype, crucial for preclinical studies and clinical application of Artemis gene transfer in the treatment of human SCID-A.

Original languageEnglish (US)
Pages (from-to)865-875
Number of pages11
JournalHuman Gene Therapy
Volume21
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Severe Combined Immunodeficiency
Cell Survival
V(D)J Recombination
Phosphoglycerate Kinase
Genes
Peptide Elongation Factor 1
Phenotype
Poisons
Endonucleases
Genetic Recombination
DNA Damage
Cell Cycle
B-Lymphocytes
Radiation
T-Lymphocytes
Clinical Studies

Cite this

Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer. / Multhaup, Megan; Karlen, Andrea D.; Swanson, Debra L.; Wilber, Andrew; Somia, Nikunj V; Cowan, Morton J.; Mc Ivor, R S.

In: Human Gene Therapy, Vol. 21, No. 7, 01.07.2010, p. 865-875.

Research output: Contribution to journalArticle

Multhaup, Megan ; Karlen, Andrea D. ; Swanson, Debra L. ; Wilber, Andrew ; Somia, Nikunj V ; Cowan, Morton J. ; Mc Ivor, R S. / Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer. In: Human Gene Therapy. 2010 ; Vol. 21, No. 7. pp. 865-875.
@article{764912ac8f164e0dbe2cf95e246c53e3,
title = "Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer",
abstract = "Artemis is a hairpin-opening endonuclease involved in nonhomologous end-joining and V(D)J recombination. Deficiency of Artemis results in radiation-sensitive severe combined immunodeficiency (SCID) characterized by complete absence of T and B cells due to an arrest at the receptor recombination stage. We have generated several lentiviral vectors for transduction of the Artemis sequence, intending to complement the deficient phenotype. We found that transduction by a lentiviral vector in which Artemis is regulated by a strong EF-1α promoter resulted in a dose-dependent loss of cell viability due to perturbed cell cycle distribution, increased DNA damage, and increased apoptotic cell frequency. This toxic response was not observed in cultures exposed to identical amounts of control vector. Loss of cell viability was also observed in cells transfected with an Artemis expression construct, indicating that toxicity is independent of lentiviral transduction. Reduced toxicity was observed when cells were transduced with a moderate-strength phosphoglycerate kinase promoter to regulate Artemis expression. These results present a novel challenge in the establishment of conditions that support Artemis expression at levels that are nontoxic yet sufficient to correct the T-B - phenotype, crucial for preclinical studies and clinical application of Artemis gene transfer in the treatment of human SCID-A.",
author = "Megan Multhaup and Karlen, {Andrea D.} and Swanson, {Debra L.} and Andrew Wilber and Somia, {Nikunj V} and Cowan, {Morton J.} and {Mc Ivor}, {R S}",
year = "2010",
month = "7",
day = "1",
doi = "10.1089/hum.2009.162",
language = "English (US)",
volume = "21",
pages = "865--875",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer

AU - Multhaup, Megan

AU - Karlen, Andrea D.

AU - Swanson, Debra L.

AU - Wilber, Andrew

AU - Somia, Nikunj V

AU - Cowan, Morton J.

AU - Mc Ivor, R S

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Artemis is a hairpin-opening endonuclease involved in nonhomologous end-joining and V(D)J recombination. Deficiency of Artemis results in radiation-sensitive severe combined immunodeficiency (SCID) characterized by complete absence of T and B cells due to an arrest at the receptor recombination stage. We have generated several lentiviral vectors for transduction of the Artemis sequence, intending to complement the deficient phenotype. We found that transduction by a lentiviral vector in which Artemis is regulated by a strong EF-1α promoter resulted in a dose-dependent loss of cell viability due to perturbed cell cycle distribution, increased DNA damage, and increased apoptotic cell frequency. This toxic response was not observed in cultures exposed to identical amounts of control vector. Loss of cell viability was also observed in cells transfected with an Artemis expression construct, indicating that toxicity is independent of lentiviral transduction. Reduced toxicity was observed when cells were transduced with a moderate-strength phosphoglycerate kinase promoter to regulate Artemis expression. These results present a novel challenge in the establishment of conditions that support Artemis expression at levels that are nontoxic yet sufficient to correct the T-B - phenotype, crucial for preclinical studies and clinical application of Artemis gene transfer in the treatment of human SCID-A.

AB - Artemis is a hairpin-opening endonuclease involved in nonhomologous end-joining and V(D)J recombination. Deficiency of Artemis results in radiation-sensitive severe combined immunodeficiency (SCID) characterized by complete absence of T and B cells due to an arrest at the receptor recombination stage. We have generated several lentiviral vectors for transduction of the Artemis sequence, intending to complement the deficient phenotype. We found that transduction by a lentiviral vector in which Artemis is regulated by a strong EF-1α promoter resulted in a dose-dependent loss of cell viability due to perturbed cell cycle distribution, increased DNA damage, and increased apoptotic cell frequency. This toxic response was not observed in cultures exposed to identical amounts of control vector. Loss of cell viability was also observed in cells transfected with an Artemis expression construct, indicating that toxicity is independent of lentiviral transduction. Reduced toxicity was observed when cells were transduced with a moderate-strength phosphoglycerate kinase promoter to regulate Artemis expression. These results present a novel challenge in the establishment of conditions that support Artemis expression at levels that are nontoxic yet sufficient to correct the T-B - phenotype, crucial for preclinical studies and clinical application of Artemis gene transfer in the treatment of human SCID-A.

UR - http://www.scopus.com/inward/record.url?scp=77954906403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954906403&partnerID=8YFLogxK

U2 - 10.1089/hum.2009.162

DO - 10.1089/hum.2009.162

M3 - Article

C2 - 20163250

AN - SCOPUS:77954906403

VL - 21

SP - 865

EP - 875

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 7

ER -